Study Exclusion reasons Remarks Reference(s)
CheckMate 511, 2019 randomized controlled trial phase IIIb/IV  
Wolchok, 2010 - inadequate or absent control group

Wolchok Lancet Oncol. 2010; 11:155-64 10.1016/S1470-2045(09)70334-1

Wolchok Ann. Oncol. 2013; 24:2174-80 10.1093/annonc/mdt161

 
Amaria, 2018 - inadequate or absent control group

Amaria Nat. Med. 2018; 24:1649-1654 10.1038/s41591-018-0197-1

 
Hersh, 2011 - inadequate or absent control group

Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8

 
Tarhini, 2019 - inadequate or absent control group

Tarhini Clin. Cancer Res. 2019; 25:524-532 10.1158/1078-0432.CCR-18-2258

 
Long, 2018 - not relevant exposure

Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6

 
Blank, 2018 - not relevant study design

Blank Nat. Med. 2018; 24:1655-1661 10.1038/s41591-018-0198-0

 
Long, 2018 - not relevant study design

Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6

 
Lebbé, 2019 - not relevant outcome

Lebbé J. Clin. Oncol. 2019; 37:867-875 10.1200/JCO.18.01998

 
OpACIN-neo, 2019 - not relevant outcome

Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2